Table 3

Multivariate analysis of poor psychological outcomes: survivor and survivor subgroups compared with siblings

Anxiety
Depression
Somatic distress
Global distress
OR (95% CI)POR (95% CI)POR (95% CI)POR (95% CI)P
Siblings 1.00  1.00  1.00  1.00  
Survivors 1.12 (0.47-2.67) .80 1.15 (0.60-2.18) .67 2.88 (1.44-5.76) .003 1.79 (0.81-3.93) .15 
By primary cancer diagnosis         
    Aplastic anemia 0.72 (0.13-3.97) .70 0.72 (0.21-2.52) .61 2.06 (0.62-6.80) .23 1.34 (0.35-5.16) .67 
    Chronic myeloid leukemia 1.01 (0.36-2.79) .99 1.34 (0.64-2.81) .43 3.53 (1.65-7.55) .001 2.19 (0.92-5.24) .08 
    Acute myeloid leukemia 1.14 (0.41-3.16) .81 1.47 (0.70-3.06) .31 3.25 (1.50-7.01) .003 1.88 (0.77-4.57) .16 
    Hodgkin lymphoma 0.20 (0.02-1.75) .14 0.21 (0.04-1.00) .05 2.18 (0.82-5.81) .12 0.53 (0.13-2.23) .39 
    Non-Hodgkin lymphoma 1.64 (0.59-4.55) .34 1.14 (0.51-2.58) .75 2.77 (1.24-6.21) .01 2.43 (0.97-6.08) .06 
    Acute lymphoblastic leukemia 1.32 (0.40-4.37) .65 1.52 (0.64-3.59) .34 2.35 (0.91-6.08) .08 1.53 (0.53-4.43) .43 
    Multiple myeloma 1.06 (0.22-5.09) .95 0.60 (0.14-2.53) .49 4.45 (1.53-12.92) .01 1.26 (0.31-5.19) .75 
    Others 1.45 (0.28-7.53) .66 0.96 (0.25-3.76) .96 0.47 (0.06-3.90) .49 1.16 (0.22-6.01) .86 
By stem cell donor         
    Autologous HCT 1.01 (0.39-2.58) .99 1.02 (0.51-2.06) .95 2.60 (1.25-5.38) .01 1.53 (0.66-3.55) .32 
    Allogeneic, sibling donor 1.15 (0.45-2.92) .78 1.34 (0.68-2.65) .40 2.88 (1.38-6.02) .00 1.96 (0.85-4.49) .11 
    Allogeneic, unrelated donor 1.54 (0.48-4.90) .47 0.91 (0.35-2.36) .85 4.32 (1.84-10.18) .001 2.28 (0.83-6.21) .11 
By risk of relapse at HCT         
    Standard risk 0.89 (0.32-2.44) .82 1.15 (0.55-2.39) .71 2.67 (1.22-5.84) .01 1.75 (0.73-4.18) .21 
    High risk 1.84 (0.64-5.29) .26 1.17 (0.51-2.68) .72 4.18 (1.79-9.74) .001 1.99 (0.76-5.24) .16 
By transplant regimens         
    Chemotherapy alone 0.70 (0.16-3.11) .64 0.75 (0.26-2.20) .60 2.42 (0.87-6.79) .09 0.90 (0.25-3.22) .87 
    Total body irradiation–based 1.24 (0.47-3.24) .66 1.23 (0.60-2.51) .57 3.15 (1.46-6.76) .003 2.00 (0.85-4.70) .11 
By cGVHD status (among allogeneic HCT survivors only)         
    No 1.17 (0.41-3.33) .77 0.89 (0.40-1.99) .78 2.32 (1.01-5.33) .05 1.32 (0.51-3.41) .56 
    Active cGVHD 1.96 (0.66-5.79) .22 1.40 (0.60-3.25) .44 5.14 (2.21-11.89) < .001 3.04 (1.17-7.88) .02 
    Resolved cGVHD 0.56 (0.16-1.99) .37 1.34 (0.60-3.00) .47 2.49 (1.04-5.97) .04 1.61 (0.61-4.28) .34 
By exposure to immunosuppressants (among allogeneic HCT survivors only)         
    Use of any immunosuppression 1.23 (0.47-3.19) .68 1.20 (0.59-2.44) .61 3.00 (1.40-6.43) .005 1.90 (0.81-4.44) .14 
    Methotrexate 1.22 (0.46-0.00) .69 1.06 (0.51-2.21) .87 3.15 (1.46-6.79) .08 1.75 (0.73-4.19) .21 
    Cyclosporine 1.22 (0.46-3.26) .69 1.46 (0.71-2.99) .31 3.32 (1.54-7.15) .003 2.04 (0.86-4.85) .11 
    Prednisone 1.63 (0.62-4.33) .33 1.53 (0.74-3.18) .25 3.76 (1.72-8.21) .106 2.46 (1.02-5.91) .04 
Anxiety
Depression
Somatic distress
Global distress
OR (95% CI)POR (95% CI)POR (95% CI)POR (95% CI)P
Siblings 1.00  1.00  1.00  1.00  
Survivors 1.12 (0.47-2.67) .80 1.15 (0.60-2.18) .67 2.88 (1.44-5.76) .003 1.79 (0.81-3.93) .15 
By primary cancer diagnosis         
    Aplastic anemia 0.72 (0.13-3.97) .70 0.72 (0.21-2.52) .61 2.06 (0.62-6.80) .23 1.34 (0.35-5.16) .67 
    Chronic myeloid leukemia 1.01 (0.36-2.79) .99 1.34 (0.64-2.81) .43 3.53 (1.65-7.55) .001 2.19 (0.92-5.24) .08 
    Acute myeloid leukemia 1.14 (0.41-3.16) .81 1.47 (0.70-3.06) .31 3.25 (1.50-7.01) .003 1.88 (0.77-4.57) .16 
    Hodgkin lymphoma 0.20 (0.02-1.75) .14 0.21 (0.04-1.00) .05 2.18 (0.82-5.81) .12 0.53 (0.13-2.23) .39 
    Non-Hodgkin lymphoma 1.64 (0.59-4.55) .34 1.14 (0.51-2.58) .75 2.77 (1.24-6.21) .01 2.43 (0.97-6.08) .06 
    Acute lymphoblastic leukemia 1.32 (0.40-4.37) .65 1.52 (0.64-3.59) .34 2.35 (0.91-6.08) .08 1.53 (0.53-4.43) .43 
    Multiple myeloma 1.06 (0.22-5.09) .95 0.60 (0.14-2.53) .49 4.45 (1.53-12.92) .01 1.26 (0.31-5.19) .75 
    Others 1.45 (0.28-7.53) .66 0.96 (0.25-3.76) .96 0.47 (0.06-3.90) .49 1.16 (0.22-6.01) .86 
By stem cell donor         
    Autologous HCT 1.01 (0.39-2.58) .99 1.02 (0.51-2.06) .95 2.60 (1.25-5.38) .01 1.53 (0.66-3.55) .32 
    Allogeneic, sibling donor 1.15 (0.45-2.92) .78 1.34 (0.68-2.65) .40 2.88 (1.38-6.02) .00 1.96 (0.85-4.49) .11 
    Allogeneic, unrelated donor 1.54 (0.48-4.90) .47 0.91 (0.35-2.36) .85 4.32 (1.84-10.18) .001 2.28 (0.83-6.21) .11 
By risk of relapse at HCT         
    Standard risk 0.89 (0.32-2.44) .82 1.15 (0.55-2.39) .71 2.67 (1.22-5.84) .01 1.75 (0.73-4.18) .21 
    High risk 1.84 (0.64-5.29) .26 1.17 (0.51-2.68) .72 4.18 (1.79-9.74) .001 1.99 (0.76-5.24) .16 
By transplant regimens         
    Chemotherapy alone 0.70 (0.16-3.11) .64 0.75 (0.26-2.20) .60 2.42 (0.87-6.79) .09 0.90 (0.25-3.22) .87 
    Total body irradiation–based 1.24 (0.47-3.24) .66 1.23 (0.60-2.51) .57 3.15 (1.46-6.76) .003 2.00 (0.85-4.70) .11 
By cGVHD status (among allogeneic HCT survivors only)         
    No 1.17 (0.41-3.33) .77 0.89 (0.40-1.99) .78 2.32 (1.01-5.33) .05 1.32 (0.51-3.41) .56 
    Active cGVHD 1.96 (0.66-5.79) .22 1.40 (0.60-3.25) .44 5.14 (2.21-11.89) < .001 3.04 (1.17-7.88) .02 
    Resolved cGVHD 0.56 (0.16-1.99) .37 1.34 (0.60-3.00) .47 2.49 (1.04-5.97) .04 1.61 (0.61-4.28) .34 
By exposure to immunosuppressants (among allogeneic HCT survivors only)         
    Use of any immunosuppression 1.23 (0.47-3.19) .68 1.20 (0.59-2.44) .61 3.00 (1.40-6.43) .005 1.90 (0.81-4.44) .14 
    Methotrexate 1.22 (0.46-0.00) .69 1.06 (0.51-2.21) .87 3.15 (1.46-6.79) .08 1.75 (0.73-4.19) .21 
    Cyclosporine 1.22 (0.46-3.26) .69 1.46 (0.71-2.99) .31 3.32 (1.54-7.15) .003 2.04 (0.86-4.85) .11 
    Prednisone 1.63 (0.62-4.33) .33 1.53 (0.74-3.18) .25 3.76 (1.72-8.21) .106 2.46 (1.02-5.91) .04 

OR indicates odds ratio; CI, confidence interval; HCT, hematopoietic cell transplantation; and cGVHD, chronic GVHD.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal